[Treatment of chronic recurrent erysipelas with streptococcal vaccine].
Identifieur interne : 005668 ( PubMed/Checkpoint ); précédent : 005667; suivant : 005669[Treatment of chronic recurrent erysipelas with streptococcal vaccine].
Auteurs : U F Haustein ; U. Biella ; I. Tausch ; H. KnöllSource :
- Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete [ 0017-8470 ] ; 1989.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Association thérapeutique, Benzathine benzylpénicilline (administration et posologie), Calendrier vaccinal, Femelle, Humains, Mâle, Récidive, Streptococcus pyogenes (immunologie), Sujet âgé, Vaccins antibactériens (administration et posologie), Érysipèle (), Érysipèle (immunologie).
- MESH :
- administration et posologie : Benzathine benzylpénicilline, Vaccins antibactériens.
- immunologie : Streptococcus pyogenes, Érysipèle.
- Adulte, Adulte d'âge moyen, Association thérapeutique, Calendrier vaccinal, Femelle, Humains, Mâle, Récidive, Sujet âgé, Érysipèle.
English descriptors
- KwdEn :
- MESH :
- chemical , administration & dosage : Bacterial Vaccines, Penicillin G Benzathine.
- immunology : Erysipelas, Streptococcus pyogenes.
- therapy : Erysipelas.
- Adult, Aged, Combined Modality Therapy, Female, Humans, Immunization Schedule, Male, Middle Aged, Recurrence.
Abstract
One hundred patients suffering from relapsing erysipelas were treated with streptococcal vaccine consisting of a phenol- und heat-inactivated mixture of 12 different types of streptococci. Simultaneously the entry point was cured and general disposition and local terrain factors were treated. In the majority of cases further relapses were avoided or their frequency reduced. The results of the treatment with streptococcal vaccine were compared with those of long-term benzathine-penicillin therapy in 47 patients. The vaccine has proved to be equivalent to the penicillin therapy and can be recommended as a real alternative to it for prevention of further infections and late sequelae, especially those of chronic lymphedema. The beneficial therapeutic effect of the vaccine is probably attributable to a non-specific immune stimulation. A partial cellular immune defect involving the protective M-antigen together with simultaneous partial abnormalities of immune reactivity is discussed as a cause of relapsing erysipelas.
PubMed: 2659550
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:2659550Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Treatment of chronic recurrent erysipelas with streptococcal vaccine].</title><author><name sortKey="Haustein, U F" sort="Haustein, U F" uniqKey="Haustein U" first="U F" last="Haustein">U F Haustein</name><affiliation><nlm:affiliation>Dermatologische Klinik und Poliklinik, Karl-Marx-Universität Leipzig.</nlm:affiliation><wicri:noCountry code="subField">Karl-Marx-Universität Leipzig</wicri:noCountry></affiliation></author><author><name sortKey="Biella, U" sort="Biella, U" uniqKey="Biella U" first="U" last="Biella">U. Biella</name></author><author><name sortKey="Tausch, I" sort="Tausch, I" uniqKey="Tausch I" first="I" last="Tausch">I. Tausch</name></author><author><name sortKey="Knoll, H" sort="Knoll, H" uniqKey="Knoll H" first="H" last="Knöll">H. Knöll</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1989">1989</date><idno type="RBID">pubmed:2659550</idno><idno type="pmid">2659550</idno><idno type="wicri:Area/PubMed/Corpus">006013</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">006013</idno><idno type="wicri:Area/PubMed/Curation">006013</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">006013</idno><idno type="wicri:Area/PubMed/Checkpoint">006013</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">006013</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Treatment of chronic recurrent erysipelas with streptococcal vaccine].</title><author><name sortKey="Haustein, U F" sort="Haustein, U F" uniqKey="Haustein U" first="U F" last="Haustein">U F Haustein</name><affiliation><nlm:affiliation>Dermatologische Klinik und Poliklinik, Karl-Marx-Universität Leipzig.</nlm:affiliation><wicri:noCountry code="subField">Karl-Marx-Universität Leipzig</wicri:noCountry></affiliation></author><author><name sortKey="Biella, U" sort="Biella, U" uniqKey="Biella U" first="U" last="Biella">U. Biella</name></author><author><name sortKey="Tausch, I" sort="Tausch, I" uniqKey="Tausch I" first="I" last="Tausch">I. Tausch</name></author><author><name sortKey="Knoll, H" sort="Knoll, H" uniqKey="Knoll H" first="H" last="Knöll">H. Knöll</name></author></analytic><series><title level="j">Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete</title><idno type="ISSN">0017-8470</idno><imprint><date when="1989" type="published">1989</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Bacterial Vaccines (administration & dosage)</term><term>Combined Modality Therapy</term><term>Erysipelas (immunology)</term><term>Erysipelas (therapy)</term><term>Female</term><term>Humans</term><term>Immunization Schedule</term><term>Male</term><term>Middle Aged</term><term>Penicillin G Benzathine (administration & dosage)</term><term>Recurrence</term><term>Streptococcus pyogenes (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Association thérapeutique</term><term>Benzathine benzylpénicilline (administration et posologie)</term><term>Calendrier vaccinal</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Récidive</term><term>Streptococcus pyogenes (immunologie)</term><term>Sujet âgé</term><term>Vaccins antibactériens (administration et posologie)</term><term>Érysipèle ()</term><term>Érysipèle (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Bacterial Vaccines</term><term>Penicillin G Benzathine</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Benzathine benzylpénicilline</term><term>Vaccins antibactériens</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Streptococcus pyogenes</term><term>Érysipèle</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Erysipelas</term><term>Streptococcus pyogenes</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Erysipelas</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Combined Modality Therapy</term><term>Female</term><term>Humans</term><term>Immunization Schedule</term><term>Male</term><term>Middle Aged</term><term>Recurrence</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Association thérapeutique</term><term>Calendrier vaccinal</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Récidive</term><term>Sujet âgé</term><term>Érysipèle</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">One hundred patients suffering from relapsing erysipelas were treated with streptococcal vaccine consisting of a phenol- und heat-inactivated mixture of 12 different types of streptococci. Simultaneously the entry point was cured and general disposition and local terrain factors were treated. In the majority of cases further relapses were avoided or their frequency reduced. The results of the treatment with streptococcal vaccine were compared with those of long-term benzathine-penicillin therapy in 47 patients. The vaccine has proved to be equivalent to the penicillin therapy and can be recommended as a real alternative to it for prevention of further infections and late sequelae, especially those of chronic lymphedema. The beneficial therapeutic effect of the vaccine is probably attributable to a non-specific immune stimulation. A partial cellular immune defect involving the protective M-antigen together with simultaneous partial abnormalities of immune reactivity is discussed as a cause of relapsing erysipelas.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2659550</PMID><DateCreated><Year>1989</Year><Month>07</Month><Day>19</Day></DateCreated><DateCompleted><Year>1989</Year><Month>07</Month><Day>19</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0017-8470</ISSN><JournalIssue CitedMedium="Print"><Volume>40</Volume><Issue>4</Issue><PubDate><Year>1989</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete</Title><ISOAbbreviation>Hautarzt</ISOAbbreviation></Journal><ArticleTitle>[Treatment of chronic recurrent erysipelas with streptococcal vaccine].</ArticleTitle><Pagination><MedlinePgn>215-21</MedlinePgn></Pagination><Abstract><AbstractText>One hundred patients suffering from relapsing erysipelas were treated with streptococcal vaccine consisting of a phenol- und heat-inactivated mixture of 12 different types of streptococci. Simultaneously the entry point was cured and general disposition and local terrain factors were treated. In the majority of cases further relapses were avoided or their frequency reduced. The results of the treatment with streptococcal vaccine were compared with those of long-term benzathine-penicillin therapy in 47 patients. The vaccine has proved to be equivalent to the penicillin therapy and can be recommended as a real alternative to it for prevention of further infections and late sequelae, especially those of chronic lymphedema. The beneficial therapeutic effect of the vaccine is probably attributable to a non-specific immune stimulation. A partial cellular immune defect involving the protective M-antigen together with simultaneous partial abnormalities of immune reactivity is discussed as a cause of relapsing erysipelas.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Haustein</LastName><ForeName>U F</ForeName><Initials>UF</Initials><AffiliationInfo><Affiliation>Dermatologische Klinik und Poliklinik, Karl-Marx-Universität Leipzig.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biella</LastName><ForeName>U</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Tausch</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Knöll</LastName><ForeName>H</ForeName><Initials>H</Initials></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Die Behandlung des chronisch-rezidivierenden Erysipels mit Streptokokkenvakzine.</VernacularTitle></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Hautarzt</MedlineTA><NlmUniqueID>0372755</NlmUniqueID><ISSNLinking>0017-8470</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001428">Bacterial Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>RIT82F58GK</RegistryNumber><NameOfSubstance UI="D010401">Penicillin G Benzathine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001428" MajorTopicYN="N">Bacterial Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004886" MajorTopicYN="N">Erysipelas</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007115" MajorTopicYN="N">Immunization Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010401" MajorTopicYN="N">Penicillin G Benzathine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013297" MajorTopicYN="N">Streptococcus pyogenes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1989</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1989</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1989</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2659550</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list></list><tree><noCountry><name sortKey="Biella, U" sort="Biella, U" uniqKey="Biella U" first="U" last="Biella">U. Biella</name><name sortKey="Haustein, U F" sort="Haustein, U F" uniqKey="Haustein U" first="U F" last="Haustein">U F Haustein</name><name sortKey="Knoll, H" sort="Knoll, H" uniqKey="Knoll H" first="H" last="Knöll">H. Knöll</name><name sortKey="Tausch, I" sort="Tausch, I" uniqKey="Tausch I" first="I" last="Tausch">I. Tausch</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005668 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 005668 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:2659550
|texte= [Treatment of chronic recurrent erysipelas with streptococcal vaccine].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:2659550" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |